Phase 1/2 study of spevatamig (PT886) in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).
Anwaar Saeed(University of Pittsburgh Medical Center), Harshabad Singh(Brigham and Women's Hospital), R. Laeufle(Therapeutics Clinical Research), N. Uboha(University of Wisconsin Carbone Cancer Center), Nicholas C. DeVito(Duke Medical Center), Naomi Fei(University of Iowa), Grace H. McGregor(Therapeutics Clinical Research), A. Spira(Virginia Cancer Specialists), Ming Wang(Wenzhou Medical University), Satya Das(St Bartholomew's Hospital), Michael J. Overman(The University of Texas MD Anderson Cancer Center), Hui Zou(Therapeutics Clinical Research), Jason T. Henry(Sarah Cannon Research Institute), Dani Ran Castillo(Loma Linda University)
Cited by 2
Related Papers
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge
|Annals of Oncology|2018|239
Clinical Characteristics and Outcomes of STEMI Patients With Cardiogenic Shock and Cardiac Arrest
|JACC: Cardiovascular Interventions|2020|86
Angioimmunoblastic T‐cell lymphoma contains multiple clonal T‐cell populations derived from a common <i>TET2</i> mutant progenitor cell
|The Journal of Pathology|2019|85
SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity
|Nucleic Acids Research|2014|64
The prognosis of <i>MYC</i> translocation positive diffuse large B‐cell lymphoma depends on the second hit
|The Journal of Pathology Clinical Research|2015|62